| 王国祥,赵 弘,惠吴函.硼替佐米为基础的方案治疗初治POEMS综合征患者不良反应分析[J].肿瘤学杂志,2020,26(2):2-106. |
| 硼替佐米为基础的方案治疗初治POEMS综合征患者不良反应分析 |
| Adverse Effects of Bortezomib-based Regimen in Treatment of Patients with POEMS Syndrome |
| 投稿时间：2019-09-10 |
| DOI：10.11735/j.issn.1671-170X.2020.02.B006 |
|
 |
| 中文关键词: POEMS综合征 硼替佐米 不良反应 |
| 英文关键词:POEMS syndrome bortezomib adverse effect |
| 基金项目: |
|
| 摘要点击次数: 1118 |
| 全文下载次数: 305 |
| 中文摘要: |
| 摘 要：［目的］ 分析硼替佐米为基础的方案治疗初治POEMS综合征患者的不良反应，评估其安全性。［方法］ 收集22例初治POEMS综合征患者的临床资料，回顾性分析治疗期间出现的各种不良反应，比较硼替佐米组（n=11）与非硼替佐米组（n=11）不良反应发生率的差异。［结果］ 两个疗程后，硼替佐米组达到VEGF缓解的比例为60%，非硼替佐米组为18.2%，两组差异无统计学意义（P=0.080）；四个疗程后硼替佐米组达VEGF缓解的比例为100%，非硼替佐米组为54.5%，两组差异有统计学意义（P=0.035）。硼替佐米组患者在治疗过程中出现感觉异常加重的比例显著高于非硼替佐米组（36.4% vs 4.2%，P<0.001），但均仅发生于化疗过程中，化疗间歇期无加重，且随治疗延续而逐渐好转。两组患者治疗后，运动功能均获得显著性恢复。其他不良反应包括感染、血小板减少、肝功能异常等。［结论］ 硼替佐米为基础的方案治疗POEMS综合征起效快、缓解率高、不良反应可耐受，有可能成为初治POEMS综合征患者的一线治疗选择。 |
| 英文摘要: |
| Abstract：［Objective］ To analysis the adverse effects of a bortezomib-based regimen in treatment of patients with newly diagnosed POEMS (polyneuropathy， organomegaly， endocrinopathy， monoclonal plasm cell-proliferative disorder，and skin changes) syndrome. ［Methods］ The clinical data of 22 patients with newly diagnosed POEMS syndrome were retrospectively reviewed. The differences in adverse reactions between patients receiving bortezomib(n=11) and those not receiving bortezomib(n=11) were compared. ［Results］ After two courses of treatment, the rate of VEGF remission in bortezomib group was 60%, and that in non-bortezomib group was 18.2%(P=0.080). After four courses of treatment, the rate of VEGF remission in bortezomib group was 100%, and that in non-bortezomib group was 54.5%(P=0.035). The proportion of patients with aggravation ofparaesthesia in bortezomib group during treatment was significantly higher than that in non-bortezomib group(36.4% vs 4.2%, P<0.001), but the symptoms were not exacerbated during chemotherapy intermission, and gradually improved as the treatment continued. After treatment, the motor function of both groups recovered significantly. Other adverse reactions included infection, thrombocytopenia and abnormal liver function.［Conclusion］ The bortezomib-based regimen for the treatment of POEMS syndrome has a fast onset, high remission rate, and tolerable adverse reactions. It may become the first-line treatment option for patients with newly diagnosed POEMS syndrome, but further studies with expanded cases are necessary. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|